BioSniper
Phase 3 Readout~month

Phase 3 Topline: ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuva

April 1, 2027
Company
CG Oncology, Inc. (CGON)
Indication
Stage II Breast Cancer; HER2-negative Breast Cancer; Stage IIIA Breast Cancer

Other upcoming events for CGON

Phase 3 ReadoutPhase 3 Topline: An Open-label, Rollover Study of Futibatinib in Patients Previously Enrolled in an Antecedent Futiba
Apr 30, 2027
Phase 3 ReadoutPhase 3 Topline: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and
May 27, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma
Jun 30, 2027
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cispla
Jun 30, 2027
Phase 3 ReadoutPhase 3 Topline: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
Aug 1, 2027

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
CGON OverviewPDUFA DatesPhase 3 Readouts
BioSniper

AI-Powered Biotech Data Intelligence Platform

Product

  • Pricing
  • FAQ

Resources

  • Event Calendar
  • PDUFA Calendar
  • AdCom Schedule
  • Blog
  • About

Data & Tools

  • Cash Runway Calculator
  • Trial Success Rates
  • FDA Review Timelines
  • PDUFA Complete Guide
  • Reading FDA AdCom Results

Legal

  • Privacy Policy
  • Terms of Service
  • Refund Policy
  • Contact Us

BioSniper is a data analytics SaaS tool for research purposes only. It does not constitute professional advice of any kind. Users should independently verify data and make their own decisions.

© 2026 Biosniper All rights reserved.Payments powered by Paddle